TCM
RVNC

Tang Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Tang Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,500,000
Closed -$13M – 193
2024
Q3 		$13M Buy
2,500,000
+2,100,000
+525% +$10.4M 0.93% 34
2024
Q2 		$1.03M Buy
400,000
+200,000
+100% +$683K 0.1% 93
2024
Q1 		$984K Buy
+200,000
New +$1.18M 0.1% 88
2022
Q4 		– Sell
-287,500
Closed -$7.76M – 107
2022
Q3 		$7.76M Buy
+287,500
New +$5.83M 0.95% 32

Other funds holding RVNC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Tang Capital Management's RVNC Position: Q4 2024 in Review

Tang Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 2,500,000 shares — an estimated $13M sold.

Tang Capital Management first reported a position in RVNC in Q3 2022 and held it in 4 quarters. The position peaked at $13M in Q3 2024. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

  • Tang Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
  • Tang Capital Management sold 2,500,000 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $13M.
  • Tang Capital Management first reported a position in Revance Therapeutics, Inc. in Q3 2022 and held it in 4 quarters.
  • Tang Capital Management's Revance Therapeutics, Inc. position peaked at $13M in Q3 2024.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on Tang Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.